{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:52:44Z","timestamp":1793465564209,"version":"4.5.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo, Inc"},{"name":"AstraZeneca."},{"name":"Daiichi Sankyo, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The phase 3 DESTINY-Breast04 trial demonstrated superior efficacy and acceptable safety with trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy in previously treated patients with human epidermal growth factor receptor 2 (HER2)\u2013low metastatic breast cancer (mBC). We report the patient-reported outcomes (PROs), focusing on the hormone receptor\u2013positive cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients were randomized 2:1 to T-DXd (5.4\u00a0mg\/kg intravenously every 3 weeks) or physician\u2019s choice of chemotherapy and prospectively assessed for PRO measures. Change from baseline and time to definitive deterioration (TDD) were calculated from the EORTC QLQ-C30 and QLQ-BR45 and the EQ-5D-5L questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline global health status\/quality of life (GHS\/QoL) scores were similar between groups (T-DXd, 331 patients; physician\u2019s choice, 163 patients); there were no clinically meaningful changes while on either treatment (median duration: T-DXd, 8.2 months; physician\u2019s choice, 3.5 months). Median TDD for GHS\/QoL was delayed with T-DXd vs physician\u2019s choice (11.4 vs 7.5 months, respectively; hazard ratio, 0.69; 95% CI, 0.52-0.92). Median TDD for all prespecified PROs, including pain, favored T-DXd. In an additional analysis, the median TDD was shorter for nausea and vomiting with T-DXd vs the physician\u2019s choice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Trastuzumab deruxtecan maintained GHS\/QoL scores despite a longer treatment course compared with standard chemotherapy and delayed definitive deterioration across all prespecified PROs vs the physician\u2019s choice. Appropriate management of adverse events and use of preventive measures (ie, antiemetic prophylaxis) may further support patient health-related quality of life. These findings reinforce the benefit of T-DXd as an option for patients with HER2-low mBC. ClinicalTrials.gov: NCT03734029<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf048","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T08:08:49Z","timestamp":1740470929000},"source":"Crossref","is-referenced-by-count":17,"title":["Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician\u2019s choice of chemotherapy in patients with HER2-low mBC"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-7275","authenticated-orcid":false,"given":"Naoto T","family":"Ueno","sequence":"first","affiliation":[{"name":"Translational and Clinical Research Program, University of Hawai\u2018i Cancer Center, Honolulu , HI, 96813 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cottone","sequence":"additional","affiliation":[{"name":"Global Oncology HEOR and RWE , Daiichi Sankyo, Rome, 00142 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Dunton","sequence":"additional","affiliation":[{"name":"Global Oncology HEOR and RWE , Daiichi Sankyo , Uxbridge, UB8 1DH ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-061X","authenticated-orcid":false,"given":"William","family":"Jacot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM U1194 , Montpellier, 34298 ,\u00a0","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6479-1660","authenticated-orcid":false,"given":"Toshinari","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Kanagawa Cancer Center , Yokohama, 241-8515 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-2764","authenticated-orcid":false,"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine , Seoul, 03722 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Tokunaga","sequence":"additional","affiliation":[{"name":"Department of Translational Genomics and Targeted Therapies Group, National Hospital Organization (NHO) Kyushu Cancer Center , Fukuoka, 811-1395 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednic de Barcelona , Barcelona, 08036 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-6943","authenticated-orcid":false,"given":"Junji","family":"Tsurutani","sequence":"additional","affiliation":[{"name":"Advanced Cancer Translational Research Institute, Showa University , Tokyo, 142-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul, 06351 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S","family":"Rugo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hellen Diller Family Comprehensive Cancer Center, University of California, San Francisco , San Francisco, CA, 94115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-2249","authenticated-orcid":false,"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Breast Unit, Champalimaud Clinical Center\/Champalimaud Foundation and ABC Global Alliance , Lisbon, 1400-038 ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahi","family":"Mitri","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Oregon Health & Science University , Portland, OR 97239 ,,","place":["United States"]},{"name":"Department of Medical Oncology, British Columbia Cancer , Vancouver, BC, V5Z 1G1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Mahtani","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Miami Cancer Institute, Baptist Health South Florida , Miami, FL , 33324,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia Orbegoso","family":"Aguilar","sequence":"additional","affiliation":[{"name":"Department of Oncology Research and Development , Daiichi Sankyo France SAS, Rueil-Malmaison, 92500 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xiao","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management, Daiichi Sankyo, Inc. , Basking Ridge, NJ, 07920 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[{"name":"Breast Center, Department of Obstetrics and Gynecology, and CCC Munich, LMU University Hospital , Munich, 81377 ,\u00a0","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Cameron","sequence":"additional","affiliation":[{"name":"Edinburgh University Cancer Centre, Institute of Genetics and Cancer, University of Edinburgh , Edinburgh, EH4 2XR ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanu","family":"Modi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"key":"2025051102025365100_CIT0001","author":"Laronga"},{"key":"2025051102025365100_CIT0002","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/annonc\/mdq429","article-title":"Treatment of metastatic breast cancer: second line and beyond","volume":"22","author":"Roch\u00e9","year":"2011","journal-title":"Ann Oncol"},{"key":"2025051102025365100_CIT0003","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.mayocp.2019.04.005","article-title":"Patient reported outcomes have arrived: a practical overview for clinicians in using patient reported outcomes in oncology","volume":"94","author":"Warsame","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2025051102025365100_CIT0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jncimonographs\/lgac009","article-title":"Health economics research in cancer treatment: current challenges and future directions","volume":"2022","author":"Yu","year":"2022","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2025051102025365100_CIT0005","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12955-022-01987-x","article-title":"Patient reported outcomes in oncology: changing perspectives-a systematic review","volume":"20","author":"Silveira","year":"2022","journal-title":"Health Qual Life Outcomes"},{"key":"2025051102025365100_CIT0006","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025051102025365100_CIT0007","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21873\/invivo.11433","article-title":"Clinical relevance of routine monitoring of patient-reported outcomes versus clinician-reported outcomes in oncology","volume":"33","author":"Fiteni","year":"2019","journal-title":"In Vivo"},{"key":"2025051102025365100_CIT0008","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jval.2020.10.017","article-title":"Patient-reported outcomes as independent prognostic factors for survival in oncology: systematic review and meta-analysis","volume":"24","author":"Efficace","year":"2021","journal-title":"Value Health"},{"key":"2025051102025365100_CIT0009","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1200\/JOP.19.00329","article-title":"Prognostic significance of patient-reported outcomes in cancer","volume":"16","author":"Kerrigan","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025051102025365100_CIT0010","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/PPO.0000000000000401","article-title":"Patient-reported outcomes in integrative oncology: bridging clinical care with research","volume":"25","author":"Lopez","year":"2019","journal-title":"Cancer J"},{"key":"2025051102025365100_CIT0011","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41687-021-00308-y","article-title":"Patient-reported outcomes in breast cancer FDA drug labels and review documents","volume":"5","author":"Hong","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"2025051102025365100_CIT0012","volume-title":"Enhertu (fam-trastuzumab deruxtecan-nxki) for Injection, for Intravenous Use","year":"2022"},{"key":"2025051102025365100_CIT0013","author":"US Food and Drug Administration"},{"key":"2025051102025365100_CIT0014","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025051102025365100_CIT0015","author":"US Food and Drug Administration"},{"key":"2025051102025365100_CIT0016","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"key":"2025051102025365100_CIT0017","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","article-title":"Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer","volume":"178","author":"Cocks","year":"2023","journal-title":"Eur J Cancer."},{"key":"2025051102025365100_CIT0018","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1023\/a:1024977728719","article-title":"The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview","volume":"7","author":"Sprangers","year":"1998","journal-title":"Qual Life Res."},{"key":"2025051102025365100_CIT0019","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.annonc.2019.10.027","article-title":"An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45","volume":"31","author":"Bjelic-Radisic","year":"2020","journal-title":"Ann Oncol."},{"key":"2025051102025365100_CIT0020","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","article-title":"Psychometric properties of the EQ-5D-5L: a systematic review of the literature","volume":"30","author":"Feng","year":"2021","journal-title":"Qual Life Res."},{"key":"2025051102025365100_CIT0021","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025051102025365100_CIT0022","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jpainsymman.2009.12.023","article-title":"The association of depression and pain with health-related quality of life, disability, and health care use in cancer patients","volume":"40","author":"Kroenke","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"2025051102025365100_CIT0023","doi-asserted-by":"publisher","first-page":"101374","DOI":"10.1016\/j.esmoop.2023.101374","article-title":"Trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC) in patients (pts) with HER2-low unresectable and\/or metastatic breast cancer (mBC): a detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial","volume":"8","author":"Rugo","year":"2023","journal-title":"ESMO Open"},{"key":"2025051102025365100_CIT0024","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1213\/ane.0b013e318172f992","article-title":"Antiemetic prophylaxis for postdischarge nausea and vomiting and impact on functional quality of living during recovery in patients with high emetic risks: a prospective, randomized, double-blind comparison of two prophylactic antiemetic regimens","volume":"107","author":"Pan","year":"2008","journal-title":"Anesth Analg."},{"key":"2025051102025365100_CIT0025","doi-asserted-by":"publisher","first-page":"100553","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"key":"2025051102025365100_CIT0026","doi-asserted-by":"crossref","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"2025051102025365100_CIT0027","volume-title":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Antiemesis V.2.2024","year":"2024"},{"key":"2025051102025365100_CIT0028","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"2025051102025365100_CIT0029","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"2025051102025365100_CIT0030","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.annonc.2023.04.516","article-title":"Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol."},{"key":"2025051102025365100_CIT0031","doi-asserted-by":"publisher","first-page":"101375","DOI":"10.1016\/j.esmoop.2023.101375","article-title":"186O patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC) in patients (pts) with HER2\u2013positive (HER2+) metastatic breast cancer (mBC)","volume":"8","author":"Fehm","year":"2023","journal-title":"ESMO Open"},{"key":"2025051102025365100_CIT0032","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.breast.2021.07.008","article-title":"Quality of life of therapies for hormone receptor positive advanced\/metastatic breast cancer: regulatory aspects and clinical impact in Europe","volume":"59","author":"Moscetti","year":"2021","journal-title":"Breast"},{"key":"2025051102025365100_CIT0033","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2147\/OTT.S100499","article-title":"Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer","volume":"9","author":"Ma","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2025051102025365100_CIT0034","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"2025051102025365100_CIT0035","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/JCO.2013.54.4999","article-title":"Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis","volume":"32","author":"Di\u00e9ras","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025051102025365100_CIT0036","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3389\/fphar.2020.00445","article-title":"Toxicity and pharmacogenomic biomarkers in breast cancer chemotherapy","volume":"11","author":"Al-Mahayri","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025051102025365100_CIT0037","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/cncr.30547","article-title":"Treatment-associated toxicities reported by patients with early-stage invasive breast cancer","volume":"123","author":"Friese","year":"2017","journal-title":"Cancer"},{"key":"2025051102025365100_CIT0038","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/jnci\/djac128","article-title":"Listening to the patient voice adds value to cancer clinical trials","volume":"114","author":"Brundage","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2025051102025365100_CIT0039","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025051102025365100_CIT0040","doi-asserted-by":"crossref","first-page":"pkad002","DOI":"10.1093\/jncics\/pkad002","article-title":"Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials","volume":"7","author":"Lord-Bessen","year":"2023","journal-title":"JNCI Cancer Spectr"},{"key":"2025051102025365100_CIT0041","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jval.2020.12.015","article-title":"Does knowledge of treatment assignment affect patient report of symptoms, function, and health status? An evaluation using multiple myeloma trials","volume":"24","author":"Roydhouse","year":"2021","journal-title":"Value Health."},{"key":"2025051102025365100_CIT0042","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1002\/cam4.3335","article-title":"Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials","volume":"9","author":"Mouillet","year":"2020","journal-title":"Cancer Med"},{"key":"2025051102025365100_CIT0043","doi-asserted-by":"publisher","first-page":"l6802","DOI":"10.1136\/bmj.l6802","article-title":"Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study","volume":"368","author":"Moustgaard","year":"2020","journal-title":"BMJ"},{"key":"2025051102025365100_CIT0044","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s11136-021-02945-8","article-title":"Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review","volume":"31","author":"Anota","year":"2022","journal-title":"Qual Life Res"},{"key":"2025051102025365100_CIT0045","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1016\/j.annonc.2023.09.553","article-title":"376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician\u2019s choice (TPC) in patients (pts) with HER2-low unresectable and\/or metastatic breast cancer (mBC): updated survival results of the randomized, phase III DESTINY-Breast04 study","volume":"34","author":"Modi","year":"2023","journal-title":"Ann Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf048\/63142077\/oyaf048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf048\/63142077\/oyaf048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T02:03:01Z","timestamp":1746928981000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf048\/8128452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf048","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf048"}}